X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The purpose of this clinical study is to examine the effects of different cannabidiol doses on reducing the frequency and severity of nausea in otherwise healthy pregnant women with excessive first trimester emesis and the diagnosis of hyperemesis gravidarum.
Lead Product(s): Cannabidiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2021
Details:
Cannabidiol, is the second most prevalent active ingredient in cannabis (marijuana) used for anxiety, pain, a muscle disorder called dystonia, Parkinson disease, Crohn disease, and many other conditions.
Lead Product(s): Cannabidiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Tauriga commenced the development of a proprietary Kratom extract infused supplement chewing gum for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment).
Lead Product(s): Kratom Extract
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
Company’s proposed pharmaceutical, Cannabinoid based, chewing Gum product (sublingual absorption-delivery system) under development for the treatment of nausea derived from active chemotherapy treatment.
Lead Product(s): Cannabidiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Details:
The Company’s proposed Cannabidiol delivery system (via: sublingual absorption / oral mucosa), utilizes its proprietary Cannabidiol infused chewing gum platform.
Lead Product(s): Cannabidiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Institutional Review Board
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 13, 2021
Details:
The clinical trial has been planned as a prospective, double-blind, placebo-controlled study, to examine the: Effects of different Cannabidiol doses on reducing the frequency and severity of nausea in otherwise healthy pregnant women with excessive first trimester emesis.
Lead Product(s): Cannabidiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
